Skip to content

Issue 11-11-2013

McKesson extends international reach with Celesio buy

McKesson Corp. has agreed to acquire the German pharmaceutical distributor Celesio AG in a deal valued at about $8.3 billion (6.1 billion euros). If completed, the transaction will create a company with annual revenues of $150 billion and operations in 20 countries.

Despite new issues, health reform proceeds

With the full implementation of the Affordable Care Act rapidly approaching, efforts to enroll millions of Americans in new health plans are taking center stage in Washington and beyond. The technical failures of the federally run health insurance website, healthcare.

FDA to restrict pain medicine

The Food and Drug Administration has recommended that Vicodin and other pain medications containing hydrocodone be reclassified as Schedule II drugs. The recommendation now goes to the Department of Health and Human Services and the Drug Enforcement Administration for a final decision.

Industry groups weigh in on Medicaid, biosimilars

The Centers for Medicare & Medicaid Services (CMS) should take steps to ensure that states increase dispensing fees for Medicaid drugs in conjunction with the new federal upper limits (FULs) that are anticipated in 2014, contend the National Association of Chain Drug Stores and the National Communit

CVS: A force in beauty for 50 years

CVS/pharmacy is celebrating 50 years of beauty care by publishing a fall “Look Book” highlighting cosmetics, hair care and other product trends from the 1960s and today. The 52-page booklet notes that CVS was founded in 1963 as Consumer Value Stores, with a focus on value and ­selection.

London Drugs hones passport technology

London Drugs has become the first retailer in North America to offer passport photo services including biometric imaging technology. On July 1 Canada implemented a biometric passport, or ePassport, system.